Patent Term Extension: The Complete PTE Calculation and Regulatory Review Period Playbook
1. Why PTE Is a Financial Asset, Not an Administrative Checkbox A single additional day of patent exclusivity on Keytruda […]
Guest Content
Sell the use, not the molecule
The innovation-exclusivity-reinvestment cycle The fundamental economic engine of the innovator pharmaceutical industry functions through a self-sustaining loop. This cycle begins
Sell the use, not the molecule Read Post »
Generic Drug Development: The Complete Regulatory, IP, and Market Strategy Playbook
1. Why Generic Drugs Are the Real Backbone of Pharma Economics Generic drugs saved the U.S. healthcare system $373 billion
Generic Drug Development: The Complete Regulatory, IP, and Market Strategy Playbook Read Post »
The Pharmacy of the World at a Crossroads: Navigating Challenges and Embracing a New Era of Global Leadership in Indian Pharma
1. Executive Strategic Overview The Indian pharmaceutical industry, historically celebrated as the “Pharmacy of the World” for its unparalleled capacity
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
India’s Section 3(d): The Definitive IP Strategy Guide for Pharmaceutical and Biotech Companies
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent
The Real Cost of Essential Medicines: Manufacturing Economics, IP Architecture, and Procurement Strategy for WHO EML Drugs
Global Key Takeaways The WHO Essential Medicines List covers more than 500 drugs that health systems are expected to keep
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio
Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
Generic Drug Markets: U.S. vs. Europe. Prices, Volumes, IP Strategy, and the $445 Billion Savings Gap
Why This Comparison Matters Now The generic pharmaceutical industry generated $445 billion in U.S. system savings in 2023 alone, according
